Overview

• The radioligand 90Y‑FAPI‑46 targets fibroblast activation protein on tumor cells and associated fibroblasts to deliver precision radiation.
• Three heavily pretreated patients with solitary fibrous tumors were selected for high FAP expression confirmed by molecular analysis and 68Ga‑FAPI‑46 PET.
• Each patient received four treatment cycles, with responses assessed using 18F‑FDG and 68Ga‑FAPI‑46 PET/CT imaging.
• Post‑therapy scans showed substantial metabolic responses with tumor shrinkage or disease stabilization, alongside relief of symptoms such as severe fatigue and abdominal pain.
• The Journal of Nuclear Medicine published the case series from University Hospital Essen, noting no serious adverse events and emphasizing SFT’s limited options and the need for prospective evaluation.